VTGN News and Press, VistaGen Therapeutics Inc. From 06/30/21

These Current & Former Biotech Penny Stocks Have Seen A Strong Year So Far One of the great things about biotech penny stocks is the potential of these companies. There are very few places that offer this kind of early access to potentially life-saving treatments. If you take a ...

VistaGen Therapeutics (NASDAQ: VTGN ), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders,...

VistaGen Therapeutics, Inc. (VTGN) Q4 2021 Earnings Conference Call June 29, 2021 5:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Executive Officer Jerrold Dotson - Vice President, Chief Financial Officer and Secretary Mark Smith - Chief...

VistaGen Therapeutics (VTGN): FY GAAP EPS of -$0.49 misses by $0.27.Revenue of $1.09M beats by $0.21M.At March 31, 2021, the Company had cash and cash equivalents of approximately $103.1 million.PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in ...

PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) Management to host corporate update conference call and audio webcast today at 2:00 p.m. PT SOUTH SAN FRANCISCO, Calif., June 29, 202...

VistaGen (NASDAQ: VTGN) , a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will host a conference cal...

SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and oth...

VistaGen Therapeutics (NASDAQ: VTGN ), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders,...

At the conclusion of the 2021 Russell Indexes annual reconstitution, biopharmaceutical company VistaGen Therapeutics (VTGN) will join the Russell 2000 Index,  effective June 28 after the U.S. market opens. VistaGen is developing new generation medicines for multiple ((CNS)) diseases and ...

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxi...